Global Depressive Disorder Market: Industry Analysis & Outlook (2016-2020)
Depression is a serious mood disorder, affecting the ability to think, feel, and handle situations like sleeping, eating, or working. It is a mood disorder that causes a persistent feeling of sadness and loss of interest. It builds up a very negative perspective in the way of thinking in every single thing and damages a person’s ability to see brighter versions of any situation in life. It is of various types like major depressive disorder (MDD), perinatal depression, psychotic depression, seasonal depression and bipolar depression.
To be diagnosed with depression, the symptoms must be present for at least two weeks. It may require long-term treatment for years. There is no single cause of depression; it is likely an outcome from combinations of genetic, biochemical, environmental and physiological factors. There are several ways of treating depression depending upon each individual’s characteristics & symptoms. Most people feel better with medication, psychological counseling or both.
The global depressive disorder market is expected to grow and overcome falling revenues due to patent expiry with better innovative drugs and therapies. The US has highest depression disorder prevalence along with highest prevalence of bipolar depression & schizophrenia. With growing awareness and better access to medical facilities, the depressive disorder market is expected to grow worldwide, especially in Asia-Pacific region.
The key factors driving the growth of the depressive disorder market includes increased smoking prevalence, rising healthcare expenditure, growing female population, increasing spending on medicines and rising number of prescription drugs. However, there are certain factors hindering the growth of the market like patent expiry, severe side effects of drugs, and tough regulations. Major trends of the market include novel drug approvals, major drugs in pipeline, and growing public awareness.
The report offers an in-depth analysis of the “Global Depressive Disorder Market” segmented into global and regional markets. Competition is concentrated in the hands of few major pharmaceutical companies out of which Pfizer Inc., AstraZeneca, Eli Lilly and company, and Lundbeck have been covered in the report.
To be diagnosed with depression, the symptoms must be present for at least two weeks. It may require long-term treatment for years. There is no single cause of depression; it is likely an outcome from combinations of genetic, biochemical, environmental and physiological factors. There are several ways of treating depression depending upon each individual’s characteristics & symptoms. Most people feel better with medication, psychological counseling or both.
The global depressive disorder market is expected to grow and overcome falling revenues due to patent expiry with better innovative drugs and therapies. The US has highest depression disorder prevalence along with highest prevalence of bipolar depression & schizophrenia. With growing awareness and better access to medical facilities, the depressive disorder market is expected to grow worldwide, especially in Asia-Pacific region.
The key factors driving the growth of the depressive disorder market includes increased smoking prevalence, rising healthcare expenditure, growing female population, increasing spending on medicines and rising number of prescription drugs. However, there are certain factors hindering the growth of the market like patent expiry, severe side effects of drugs, and tough regulations. Major trends of the market include novel drug approvals, major drugs in pipeline, and growing public awareness.
The report offers an in-depth analysis of the “Global Depressive Disorder Market” segmented into global and regional markets. Competition is concentrated in the hands of few major pharmaceutical companies out of which Pfizer Inc., AstraZeneca, Eli Lilly and company, and Lundbeck have been covered in the report.
1. MARKET OVERVIEW
1.1 Introduction
1.2 Types
1.3 Causes & Symptoms
1.4 Diagnosis & Treatment
2. GLOBAL MARKET
2.1 Global Depressive Disorder Market by Value
2.2 Global Depressive Disorder Market Forecast by Value
2.3 Global Depressive Disorder Market by Region
2.4 Global Anti-Depressant Drug Market by Value
2.5 Global Anti-Depressant Drug Market Forecast by Value
2.6 Global Anti-Psychotic Drug Market by Value
2.7 Global Anti-Psychotic Drug Market Forecast by Value
3. REGIONAL MARKETS
3.1 The US
3.1.1 The US Depressive Disorder Market Forecast by Value
3.1.2 The US Mental Health Drug Prescription by Volume
3.1.3 The US Depressive Disorder Patient Prevalence Forecast
3.1.4 The US Bipolar Depression Patient Prevalence Forecast
3.1.5 The US Bipolar Depression Addressable Population Forecast
3.1.6 The US Schizophrenia Patient Prevalence Forecast
3.1.7 The US Schizophrenia Addressable Population Forecast
3.2 Europe
3.2.1 European Depressive Disorder Market Forecast by Value
3.2.2 European Bipolar Depression Patient Prevalence Forecast
3.2.3 European Bipolar Depression Addressable Population Forecast
3.2.4 European Schizophrenia Patient Prevalence Forecast
3.2.5 European Schizophrenia Addressable Population Forecast
3.3 China
3.3.1 China Anti-Depressant Drug Market by Value
3.3.2 China Anti-Depressant Drug Market Forecast by Value
3.3.3 China Anti-Psychotic Drug Market by Value
3.3.4 China Anti-Psychotic Drug Market Forecast by Value
4. MARKET DYNAMICS
4.1 Key Trends & Developments
4.1.1 Novel Drug Approvals
4.1.2 Rapid Acting Depression Drugs in Development
4.1.3 Direct-to-Customer Advertising
4.1.4 Growing Public Awareness
4.2 Growth Drivers
4.2.1 Increasing Sales of Prescription Drugs
4.2.2 Increased Spending on Medicines
4.2.3 Increased Smoking Prevalence
4.2.4 Rising Spending on Public Health Programs
4.2.5 Rising Global Health Expenditure
4.2.6 Increasing Female Population Worldwide
4.3 Challenges
4.3.1 Patent Expiry
4.3.2 Tough Drug Regulations
4.3.3 Severe Side-Effects
5. COMPETITIVE LANDSCAPE
5.1 Global Depressive Disorder Market
5.1.1 Revenue Comparison
5.2 Global Anti-Depressants Market
5.2.1 Market Share Comparison
5.2.2 Revenue Comparison
5.2.3 Product Comparison
5.3 Global Anti-Psychtoics Market
5.3.1 Market Share Comparison
5.3.2 Revenue Comparison
5.3.3 Product Comparison
6. COMPANY PROFILES
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 AstraZeneca
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Lundbeck
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
1.1 Introduction
1.2 Types
1.3 Causes & Symptoms
1.4 Diagnosis & Treatment
2. GLOBAL MARKET
2.1 Global Depressive Disorder Market by Value
2.2 Global Depressive Disorder Market Forecast by Value
2.3 Global Depressive Disorder Market by Region
2.4 Global Anti-Depressant Drug Market by Value
2.5 Global Anti-Depressant Drug Market Forecast by Value
2.6 Global Anti-Psychotic Drug Market by Value
2.7 Global Anti-Psychotic Drug Market Forecast by Value
3. REGIONAL MARKETS
3.1 The US
3.1.1 The US Depressive Disorder Market Forecast by Value
3.1.2 The US Mental Health Drug Prescription by Volume
3.1.3 The US Depressive Disorder Patient Prevalence Forecast
3.1.4 The US Bipolar Depression Patient Prevalence Forecast
3.1.5 The US Bipolar Depression Addressable Population Forecast
3.1.6 The US Schizophrenia Patient Prevalence Forecast
3.1.7 The US Schizophrenia Addressable Population Forecast
3.2 Europe
3.2.1 European Depressive Disorder Market Forecast by Value
3.2.2 European Bipolar Depression Patient Prevalence Forecast
3.2.3 European Bipolar Depression Addressable Population Forecast
3.2.4 European Schizophrenia Patient Prevalence Forecast
3.2.5 European Schizophrenia Addressable Population Forecast
3.3 China
3.3.1 China Anti-Depressant Drug Market by Value
3.3.2 China Anti-Depressant Drug Market Forecast by Value
3.3.3 China Anti-Psychotic Drug Market by Value
3.3.4 China Anti-Psychotic Drug Market Forecast by Value
4. MARKET DYNAMICS
4.1 Key Trends & Developments
4.1.1 Novel Drug Approvals
4.1.2 Rapid Acting Depression Drugs in Development
4.1.3 Direct-to-Customer Advertising
4.1.4 Growing Public Awareness
4.2 Growth Drivers
4.2.1 Increasing Sales of Prescription Drugs
4.2.2 Increased Spending on Medicines
4.2.3 Increased Smoking Prevalence
4.2.4 Rising Spending on Public Health Programs
4.2.5 Rising Global Health Expenditure
4.2.6 Increasing Female Population Worldwide
4.3 Challenges
4.3.1 Patent Expiry
4.3.2 Tough Drug Regulations
4.3.3 Severe Side-Effects
5. COMPETITIVE LANDSCAPE
5.1 Global Depressive Disorder Market
5.1.1 Revenue Comparison
5.2 Global Anti-Depressants Market
5.2.1 Market Share Comparison
5.2.2 Revenue Comparison
5.2.3 Product Comparison
5.3 Global Anti-Psychtoics Market
5.3.1 Market Share Comparison
5.3.2 Revenue Comparison
5.3.3 Product Comparison
6. COMPANY PROFILES
6.1 Pfizer Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 AstraZeneca
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Lundbeck
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
LIST OF CHARTS
Types of Depression
Causes & Symptoms of Depression
Global Depressive Disorder Market by Value (2010-2015)
Global Depressive Disorder Market Forecast by Value (2016-2020)
Global Depressive Disorder Market by Region (2015)
Global Anti-Depressant Drug Market by Value (2010-2015)
Global Anti-Depressant Drug Market Forecast by Value (2016-2020)
Global Anti-Psychotic Drug Market by Value (2010-2015)
Global Anti-Psychotic Drug Market Forecast by Value (2016-2020)
The US Depressive Disorder Market Forecast by Value (2015-2020)
The US Mental Health Drug Prescription by Volume (2011-2015)
The US Depressive Disorder Patient Prevalence Forecast (2016-2020)
The US Bipolar Depression Patient Prevalence Forecast (2016-2020)
The US Bipolar Depression Addressable Population Forecast (2016-2020)
The US Schizophrenia Patient Prevalence Forecast (2016-2020)
The US Schizophrenia Addressable Population Forecast (2016-2020)
European Depression Disorder Market Forecast by Value (2015-2020)
European Bipolar Depression Patient Prevalence Forecast (2016-2020)
European Bipolar Depression Addressable Population Forecast (2016-2020)
European Schizophrenia Patient Prevalence Forecast (2016-2020)
European Schizophrenia Addressable Population Forecast (2016-2020)
China Anti-Depressant Drug Market by Value (2010-2015)
China Anti-Depressant Drug Market Forecast by Value (2016-2020)
China Anti-Psychotic Drug Market by Value (2010-2015)
China Anti-Psychotic Drug Market Forecast by Value (2016-2020)
Increasing Sales of Prescription Drugs (2010-2015)
Global Spending on Medicines (2010-2020E)
Total Spending on Medicines in the US (2010-2015)
Global Cigarette Consumption (1940-2015)
Global Healthcare Expenditure (2009-2015)
Global Female Population (2010-2015)
Global Depressive Disorder Market Revenue Comparison (2015)
Global Anti-Depressant Market Share by Drugs (2015)
Global Anti-Depressant Drug Revenue Comparison (2018)
Global Anti-Psychotic Market Share by Drugs (2015)
Global Anti-Psychotic Drug Revenue Comparison (2020)
Pfizer Inc. Revenue by Segment (2015)
Pfizer Inc. Revenue and Net Income (2012-2015)
AstraZeneca Revenue by Segment (2015)
AstraZeneca’s Revenue (2012-2015)
Eli Lilly Revenue Share by Segments (2015)
Eli Lilly Revenue and Net Income (2011-2015)
Lundbeck’s Key Therapeutic Areas (2015)
Lundbeck’s Revenue Share by Products (2015)
Lundbeck’s Revenue and Net Income (2011-2015)
Lundbeck’s Research & Development Expenses (2011-2015)
Types of Depression
Causes & Symptoms of Depression
Global Depressive Disorder Market by Value (2010-2015)
Global Depressive Disorder Market Forecast by Value (2016-2020)
Global Depressive Disorder Market by Region (2015)
Global Anti-Depressant Drug Market by Value (2010-2015)
Global Anti-Depressant Drug Market Forecast by Value (2016-2020)
Global Anti-Psychotic Drug Market by Value (2010-2015)
Global Anti-Psychotic Drug Market Forecast by Value (2016-2020)
The US Depressive Disorder Market Forecast by Value (2015-2020)
The US Mental Health Drug Prescription by Volume (2011-2015)
The US Depressive Disorder Patient Prevalence Forecast (2016-2020)
The US Bipolar Depression Patient Prevalence Forecast (2016-2020)
The US Bipolar Depression Addressable Population Forecast (2016-2020)
The US Schizophrenia Patient Prevalence Forecast (2016-2020)
The US Schizophrenia Addressable Population Forecast (2016-2020)
European Depression Disorder Market Forecast by Value (2015-2020)
European Bipolar Depression Patient Prevalence Forecast (2016-2020)
European Bipolar Depression Addressable Population Forecast (2016-2020)
European Schizophrenia Patient Prevalence Forecast (2016-2020)
European Schizophrenia Addressable Population Forecast (2016-2020)
China Anti-Depressant Drug Market by Value (2010-2015)
China Anti-Depressant Drug Market Forecast by Value (2016-2020)
China Anti-Psychotic Drug Market by Value (2010-2015)
China Anti-Psychotic Drug Market Forecast by Value (2016-2020)
Increasing Sales of Prescription Drugs (2010-2015)
Global Spending on Medicines (2010-2020E)
Total Spending on Medicines in the US (2010-2015)
Global Cigarette Consumption (1940-2015)
Global Healthcare Expenditure (2009-2015)
Global Female Population (2010-2015)
Global Depressive Disorder Market Revenue Comparison (2015)
Global Anti-Depressant Market Share by Drugs (2015)
Global Anti-Depressant Drug Revenue Comparison (2018)
Global Anti-Psychotic Market Share by Drugs (2015)
Global Anti-Psychotic Drug Revenue Comparison (2020)
Pfizer Inc. Revenue by Segment (2015)
Pfizer Inc. Revenue and Net Income (2012-2015)
AstraZeneca Revenue by Segment (2015)
AstraZeneca’s Revenue (2012-2015)
Eli Lilly Revenue Share by Segments (2015)
Eli Lilly Revenue and Net Income (2011-2015)
Lundbeck’s Key Therapeutic Areas (2015)
Lundbeck’s Revenue Share by Products (2015)
Lundbeck’s Revenue and Net Income (2011-2015)
Lundbeck’s Research & Development Expenses (2011-2015)
LIST OF TABLES
Novel Drug Approvals for Depression Disorder (2015)
Major Rapid Acting Depression Drugs in Development (2015)
Severe Side-Effects of Depression Disorder Drugs
Global Anti-Depressants Market Comparison by Product Profile (2015)
Global Anti-Psychotics Market Comparison by Product Profile (2015)
New Products of Pfizer with FDA Approval (2015/2016)
Approvals and Upcoming Drugs (2015)
Lundbeck’s New Drugs in Development (2015)
Novel Drug Approvals for Depression Disorder (2015)
Major Rapid Acting Depression Drugs in Development (2015)
Severe Side-Effects of Depression Disorder Drugs
Global Anti-Depressants Market Comparison by Product Profile (2015)
Global Anti-Psychotics Market Comparison by Product Profile (2015)
New Products of Pfizer with FDA Approval (2015/2016)
Approvals and Upcoming Drugs (2015)
Lundbeck’s New Drugs in Development (2015)
